[225Ac]hu11B6-IgG3

[225Ac]hu11B6-IgG3 is an experimental targeted alpha-radioimmunotherapy (TAT) designed for the treatment of prostate cancer. It consists of a humanized monoclonal antibody, hu11B6, of the IgG3 subclass, conjugated to the alpha-emitting radioisotope Actinium-225 (225Ac). The antibody specifically targets human kallikrein-related peptidase 2 (hK2; KLK2), a prostate-specific enzyme that is highly expressed in prostate cancer cells and regulated by the androgen receptor. Upon binding to hK2, the complex is internalized into the cell, allowing the Actinium-225 to deliver high-energy, short-range alpha particles that cause lethal double-strand DNA breaks. The IgG3 variant was developed to explore whether its superior complement activation and Fc-gamma-receptor binding capabilities could enhance the therapeutic effect compared to the more common IgG1 subclass, although preclinical studies have shown comparable efficacy between the two.

Other names

Actinium-225-labeled hu11B6-IgG3Actinium225-labeled hu11B6-IgG3Actinium 225-labeled hu11B6-IgG3225Ac-labeled humanized 11B6 IgG3